SCHEMBL6797762

SCHEMBL6797762

COc1cccc(C(Cl)c2cc3ccccc3o2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
HTR2B P41595 5/20 0.43
DRD2 P14416 4/20 0.43
HTR1A P08908 2/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
MAOB P27338 1/20 0.43
CASP3 P42574 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
PDGFRB P09619 1/20 0.40
PDGFRA P16234 1/20 0.40
ACHE P22303 1/20 0.39
CASR P41180 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6798654 0.83 MAPT (0.48) MAPTHTR2BDRD2HTR1AMGAM
SCHEMBL8893071 0.80 RAB9A (0.42) NPC1RAB9AMAOBTDP1KMT2A
SCHEMBL6793398 0.77 MTNR1A (0.53) NPC1RAB9AKMT2AMEN1CASR
SCHEMBL952823 0.76 CASR (0.51) MAOBACHECASRSMN1; SMN2
SCHEMBL10363817 0.75 RAB9A (0.44) MAPTHTR2BDRD2HTR1AGAA
SCHEMBL8696810 0.74 CYP19A1 (0.52) MAPTNPC1RAB9AMAOBKMT2A
SCHEMBL6795411 0.74 SLC6A4 (0.47) MAPTMGAMGAASIMGAM2
SCHEMBL6797766 0.72 SLC6A2 (0.41) MAPTMGAMGAASIMGAM2
SCHEMBL8699929 0.72 CYP19A1 (0.53) MAPTNPC1RAB9AMAOBTDP1
SCHEMBL24620883 0.71 CYP19A1 (0.46) MAPTNPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040138228-A1 Novel compounds with analgesic effect ASTRAZENECA CANADA INC. 2004-07-15 US disclosed
EP-1408037-A1 Novel diarylmethylpiperazine and diarylmethylphenyl compounds with analgesic effect AstraZeneca AB (SE) 2004-04-14 EP disclosed
US-6680321-B1 4-((1-PIPERAZINYLMETHYL)-BENZAMIDE DERIVATIVES; HYPOTENSIVE AGENTS; IMMUNOMODULATORS ASTRAZENECA CANADA, INC. (CA) 2004-01-20 US disclosed
US-6130222-A Compounds with analgesic effect ASTRA PHARMA INC. (CA) 2000-10-10 US disclosed
EP-0915855-A1 NOVEL COMPOUNDS WITH ANALGESIC EFFECT Astra Pharma Inc. (CA) 1999-05-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138228-A1 Novel compounds with analgesic effect OPRL1, OPRK1, OPRM1 MAPT 2353/4885HTR2B 994/4885DRD2 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.